Fisher Scientific International Inc
Fisher Scientific International — Merrill Lynch Global Pharmaceutical, Biotech and Medical Device Conference 2004
26 slides from Fisher Scientific International's conference presentation, Feb 5, 2004

Slide 1: The World Leader in Serving Science
The World Leader in Serving Science Merrill Lynch Global Pharmaceutical, Biotech and Medical Device Conference February 5, 2004

Slide 2: Safe Harbor and Regulation G Statement
The Securities and Exchange Commission encourages companies to disclose forward- looking information so that investors can better understand a company's future prospects and make informed investment decisions. This presentation contains these types of statements, which are "forward-looking statement

Slide 3: Fisher at a Glance
Fisher at a Glance - Founded in 1902 Proprietary 4 5% Distributed 55% * Midpoint of management estimates 350,000 customers Global scientific research $20 U.S. clinical laboratory $10 2004E sales: $4.0 Bils* Growing Markets ($ Bils) Favorable market dynamics Broad Product Portfolio One stop shop Dive

Slide 4: Diverse Customer Base
7 Scientific Research 77% Clinical Lab 23% No Customer > 2.5% of Sales Diverse Customer Base Pharma 0.26 Hospitals 0.16 Reference Labs 0.07 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12

Slide 5: Market Dynamics Are Favorable
Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 R&D spending steadily increasing Market Dynamics Are Favorable Customer Base 9 Pharma/Biotech 26% Colleges & Universities 12% Medical Research 7% Other Scientific Research 32%

Slide 6: Market Dynamics Are Favorable
Pressure on drug development costs R&D spending steadily increasing Market Dynamics Are Favorable Customer Base Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 Pharma/Biotech 26% 11

Slide 7: Market Dynamics Are Favorable
Pressure on drug development costs Aging population R&D spending steadily increasing Market Dynamics Are Favorable Customer Base Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 Pharma/Biotech 26% Colleges & Universities 12% Medical Research 7% Hospitals and

Slide 8: Market Dynamics Are Favorable
Pressure on drug development costs Aging population R&D spending steadily increasing Growth in homeland security spending Market Dynamics Are Favorable Customer Base 15 Pharma 0.26 Hospitals 0.23 Other 0.32 Medical Research 0.07 Colleges and Universities 0.12 Hospitals and Reference Labs 23% Other S

Slide 9: U.S. Scientific Research Market Overview
Sources: Laboratory Products Association, SDI Inc., SAI and management estimates. $10 billion Growth Rate: 5 - 8% Scientific Research Market U.S. Market Overview U.S. R&D Spending CAGR: 9% Other 0.71 E-Merck 0.13 Fisher (including Columbia) 0.16 1960 1965 1970 1975 1980 1985 1990 1995 2003 (Excl. De

Slide 10: U.S. Clinical Laboratory Market Overview
Sources: The Freedonia Group and management estimates. U.S. Market Overview $9.5 billion Growth Rate: 4 - 5% Number of IVD Tests (Test Per Person) 3.3 3.8 4.5 5.4 6.5 IVD Tests (in Bils) 1989 1993 1998 2003 2008 East 13.3 14.5 16.5 19.1 22 Clinical Laboratory Market Other 0.85 Cardinal 0.08 Fisher (

Slide 11: Company Capabilities
The Fisher brand Global logistics Industry-leading sales force Company Capabilities

Slide 12: The Fisher Brand
100 years of serving science Broad proprietary product and service portfolio Global brand recognition Company Capabilities The Fisher Brand

Slide 13: Global Logistics Capabilities
Global Logistics Capabilities Company Capabilities 30,000 shipments daily 40 distribution facilities E-commerce systems

Slide 14: Industry-Leading Sales Force
1,500 sales reps 1,200 customer service reps Industry-Leading Sales Force Company Capabilities Supply chain solutions 300 life science, chemical and technical specialists End-user sales and support

Slide 15: Reduced Investment in Working Capital
1997 1998 1999 2000 2001 2002 2003 East 0.155 0.131 0.112 0.093 0.091 0.086 0.077 * Excludes impact of Perbio acquisition. Note: Working capital is defined as the average balance of the last four quarters of receivables plus inventories less accounts payable. Company Capabilities Reduced Investment

Slide 16: Margin Enhancement Strategy
Proprietary (45% of sales) - Self-manufactured - Private labeled - Exclusives Distributed (55% of sales) Gross Margin % Margin Enhancement Strategy 31

Slide 17: Acquisitions Drive Margin Enhancement
16 Acquisitions Drive Margin Enhancement Diagnostic Reagents Biochemicals Acros Maybridge Mimotopes Pierce HyClone Clinical Trial Services Margin Enhancement Strategy 33

Slide 18: Margin Enhancement Strategy
35 Margin Enhancement Strategy Fisherbrand Powerful Channel Position Leading Products in Key Markets Drug Discovery Drug Development Healthcare Delivery Research and Development Fisher Chemicals

Slide 19: Significant Margin Expansion
1997 1998 1999 2000 2001 2002 2003 2004F* East 0.054 0.063 0.069 0.068 0.073 0.075 0.078 0.087 * Midpoint of management estimates. Note: Operating income as a percentage of sales - excludes restructuring and non-recurring expenses. Margin Enhancement Strategy Significant Margin Expansion 330 bps 37

Slide 20: Financial Highlights
Financial Highlights

Slide 21: Sales Growth
Sales Growth ($ in billions) 1997 1998 1999 2000 2001 2002 2003 2004F* *Midpoint of management estimates - excludes the impact of foreign exchange rate changes. CAGR: 8%

Slide 22: Earnings Per Share Growth
Earnings Per Share Growth 1997 1998 1999 2000 2001 2002 2003 2004F* *Midpoint of management estimates Note: Excludes restructuring and non-recurring expenses. CAGR: 27%

Slide 23: Strong Cash Flow
Strong Cash Flow (1) Midpoint of management estimates. (2) Defined as cash flow from operations less capital expenditures divided by diluted shares outstanding. (3) Defined as free cash flow per share divided by closing share price on 12/31/03 and 2/02/04 for 2003 and 2004 respectively. (1) (2) (3)

Slide 24: Increasing Return on Committed Capital
1997 1998 1999 2000 2001 2002 2003 East 0.2 0.3 0.33 0.36 0.39 0.413 0.43 Note: Return on committed capital is defined as adjusted operating income excluding intangible amortization as a percentage of committed capital (property, plant and equipment plus accounts receivable plus inventories less acc

Slide 25: Investment Highlights
Investment Highlights Strong earnings and cash flow growth Favorable market dynamics Significant margin enhancement opportunities Strong management team

Slide 26: The World Leader in Serving Science
The World Leader in Serving Science
Source: SEC EDGAR · 8-K filed Feb 5, 2004
More decks from Fisher Scientific International Inc
Merger or Acquisition (May 2006)23 slides · May 8, 2006
Lehman Brothers Ninth Annual Global Healthcare Conference 200619 slides · Mar 8, 2006
Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 200612 slides · Feb 9, 2006
Goldman Sachs Twenty Sixth Annual Global Healthcare Conference 200511 slides · Jun 15, 2005
Banc of America Securities Health Care Conference 200511 slides · May 17, 2005
Baird Growth Stock Conference 200526 slides · May 12, 2005